Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714

What this Trial Is About

Researchers are studying the levels and distribution of activated brain microglia and macrophages in people with chronic pain and fatigue, conditions suspected to involve neuroinflammation. This study uses a special PET radiopharmaceutical called [F-18]DPA-714 that binds to a protein found in activated immune cells in the brain, allowing a non-invasive measurement of neuroinflammation. The goal is to see if individuals with fibromyalgia, chronic fatigue syndrome, or multiple sclerosis have higher neuroinflammation compared to healthy volunteers. Participants will undergo imaging with [F-18]DPA-714 PET/MRI to measure brain inflammation levels. The study includes four groups: healthy controls, fibromyalgia subjects, chronic fatigue syndrome subjects, and multiple sclerosis subjects. This is a phase 1, non-randomized interventional trial sponsored by the University of Alabama at Birmingham. The imaging procedure allows researchers to observe the presence of neuroinflammation in the brain regions of these groups. During the study, participants will have PET/MRI scans to assess neuroinflammation using the tracer [F-18]DPA-714. The main outcome measured is the difference in neuroinflammation between healthy volunteers and those with pain and fatigue conditions over a 3-year period. Researchers will monitor participants for any contraindications to MRI and ensure safety measures are followed. The study includes adults aged 18 to 65 and involves no blinding or placebo control.

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.